ACADIA PHARMACEUTICALS INC (ACAD)

US0042251084 - Common Stock

16.31  -0.28 (-1.69%)

After market: 16.37 +0.06 (+0.37%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
484.1M
9.57%		517.2M
6.84%		726.437M
40.46%		986.42M
35.79%
EBITDA
YoY % growth
-167.05M
41.11%		-221.57M
-32.64%		-67.827M
69.39%		115.61M
270.45%		N/AN/AN/A
EBIT
YoY % growth
-170.4M
40.54%		-223.6M
-31.22%		-73.379M
67.18%		109.73M
249.54%
Operating Margin
-35.20%-43.23%-10.10%11.12%
EPS
YoY % growth
-1.05
41.67%		-0.97
7.62%		-0.38
60.82%		0.68
278.73%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		0.05
119.39%
Revenue
Q2Q % growth		212.53M
79.35%
EBITDA
Q2Q % growth		16.165M
EBIT
Q2Q % growth		6.635M
112.38%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 0.28
207.69%		0.31-0.03-9.66%
Q3 2023
Q2Q % growth		 -0.40
-135.29%		-0.430.037.97%
Q2 2023
Q2Q % growth		 0.01
104.76%		-0.080.09111.87%
Q1 2023
Q2Q % growth		 -0.27
18.18%		-0.22-0.05-23.29%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 231.041M
69.26%		228.26M2.781M1.22%
Q3 2023
Q2Q % growth		 211.7M
61.97%		193.28M18.42M9.53%
Q2 2023
Q2Q % growth		 165.2M
22.73%		160.96M4.24M2.63%
Q1 2023
Q2Q % growth		 118.5M
2.60%		122.69M-4.19M-3.42%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-8.52% -75.56% -1.94% -27.11%
Revenue-0.17% -7.15% -0.03% 1.22%